Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Xiao-Hong Ding *Key Laboratory of Breast Cancer in Shanghai, Shanghai institute of infectious Disease and Biosecurity, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, People's Republic of China.
Fenfang Chen *Key Laboratory of Breast Cancer in Shanghai, Shanghai institute of infectious Disease and Biosecurity, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, People's Republic of China.
Fan Yang *Key Laboratory of Breast Cancer in Shanghai, Shanghai institute of infectious Disease and Biosecurity, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, People's Republic of China.
Gen-Hong DiKey Laboratory of Breast Cancer in Shanghai, Shanghai institute of infectious Disease and Biosecurity, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, People's Republic of China.
Zhi-Ming ShaoKey Laboratory of Breast Cancer in Shanghai, Shanghai institute of infectious Disease and Biosecurity, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, People's Republic of China.ORCID 0000-0002-4503-148X
Yi XiaoKey Laboratory of Breast Cancer in Shanghai, Shanghai institute of infectious Disease and Biosecurity, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, People's Republic of China.ORCID 0000-0003-2946-9921
Yi-Zhou JiangKey Laboratory of Breast Cancer in Shanghai, Shanghai institute of infectious Disease and Biosecurity, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, People's Republic of China.ORCID 0000-0003-3699-2630
Funding
MOST | National Key Research and Development Program of China (NKPs) 2024YFA1107400MOST | National Natural Science Foundation of China (NSFC) 82341003MOST | National Natural Science Foundation of China (NSFC) 82373167MOST | National Natural Science Foundation of China (NSFC) 82425044MOST | National Natural Science Foundation of China (NSFC) 92159301Seed Program for Research and Translation of Innovative Medical Technologies of Shanghai Municipal Commission of Health 2024ZZ2023SHDC Municipal Project for Developing Emerging and Frontier Technology in Shanghai Hospitals SHDC12021103the Shuguang Program of Shanghai Education Development Foundation and Shanghai Municipal Education Commission 24SG12
6 · The paper itself
Abstract
Luminal breast cancer is characterized by a persistent risk of recurrence and dysregulated lipid metabolism. However, the role of phase separation, a novel mechanism for the spatial compartmentalization of proteins, in lipid remodeling within the context of breast cancer remains largely unexplored. Utilizing the multiomics data from our large breast cancer cohort (n = 773), we revealed that aberrant lipid metabolism negatively impacts the prognosis of patients with luminal breast cancer. Furthermore, we deciphered that the copy number alteration-driven
Indexed as
Breast NeoplasmsLipid MetabolismCell Line, TumorFemaleFerroptosisHumansPhase SeparationPhosphorylationProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-aktDDHD2ferroptosislipid metabolismluminal breast cancerphase separation
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Phase separation of DDHD2 remodels lipid metabolism to dictate treatment sensitivity in luminal breast cancer. · full record | Socratic